{"commentary":{"count":64,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":35,"podcast":19,"youtube":10},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04526691\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"NCT04526691","nct_id":"NCT04526691","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct04526691. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":null,"arms":[{"description":"Dose Escalation and Dose Expansion: Datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab with or without platinum chemotherapy in participants with advanced or metastatic NSCLC","label":"Datopotamab deruxtecan (Dato-DXd)","type":"EXPERIMENTAL"}],"collaborators":["Merck Sharp & Dohme LLC"],"completion_date":{"date":"2026-12-31","type":"ESTIMATED"},"conditions":["Advanced or Metastatic NSCLC"],"enrollment":{"count":145,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Datopotamab deruxtecan","type":"DRUG"},{"name":"KEYTRUDA®","type":"DRUG"},{"name":"Carboplatin","type":"DRUG"},{"name":"Cisplatin","type":"DRUG"}],"last_update":"2026-05-15","lead_sponsor":"Daiichi Sankyo","official_title":"Phase 1b, Multicenter, Open-label Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1"],"primary_completion_date":{"date":"2024-04-14","type":"ACTUAL"},"primary_outcomes":[{"measure":"Number of Participants with Dose-limiting Toxicities (DLTs) and Treatment-emergent Adverse Events (TEAEs)","timeFrame":"Baseline up to Cycle 1 (Days 1 to 21) for DLTs and up to 28 days after last dose for TEAEs, up to approximately 30 months post-dose"}],"references":[{"citation":"Levy B, Paz-Ares L, Lin CC, Herbert S, Yang TY, Tolcher A, Lou Y, Zenke Y, Cortinovis D, Felip E, Domine M, Leventakos K, Calvo E, Horiike A, Pan E, Basak P, Lin D, Gu W, Chiaverelli R, Chisamore MJ, Goto Y. Datopotamab Deruxtecan Plus Pembrolizumab With or Without Platinum-Based Chemotherapy for Advanced or Metastatic NSCLC: The Phase Ib TROPION-Lung02 Trial. J Thorac Oncol. 2026 Jul;21(7):103688. doi: 10.1016/j.jtho.2026.103688. Epub 2026 Mar 21.","pmid":"41871716","type":"DERIVED"}],"start_date":{"date":"2020-09-15","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02)","url":"https://clinicaltrials.gov/study/NCT04526691"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct04526691"}